期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/ijms22031186
关键词
tau; GSK2606414; kinases; MEMRI; TMT proteomics
资金
- Alzheimer's Association [NIRG-14-322441]
- Department of Defense [AZ140097]
- NIH/NIMHD [L32 MD009205-01]
- NIH [1R21NS093440]
- NIH/NINDS [1R01 NS091329-01]
Tauopathies are a group of disorders involving neurodegeneration and cognitive decline, with limited therapeutic options due to lack of understanding of molecular mechanisms. Treating early stage tau transgenic mice with a multi-target kinase inhibitor improved brain atrophy and cognitive function, despite unchanged levels of hyperphosphorylated tau. Proteomics data identified potential therapeutic targets for tauopathy treatment.
Tauopathies are a group of more than twenty known disorders that involve progressive neurodegeneration, cognitive decline and pathological tau accumulation. Current therapeutic strategies provide only limited, late-stage symptomatic treatment. This is partly due to lack of understanding of the molecular mechanisms linking tau and cellular dysfunction, especially during the early stages of disease progression. In this study, we treated early stage tau transgenic mice with a multi-target kinase inhibitor to identify novel substrates that contribute to cognitive impairment and exhibit therapeutic potential. Drug treatment significantly ameliorated brain atrophy and cognitive function as determined by behavioral testing and a sensitive imaging technique called manganese-enhanced magnetic resonance imaging (MEMRI) with quantitative R1 mapping. Surprisingly, these benefits occurred despite unchanged hyperphosphorylated tau levels. To elucidate the mechanism behind these improved cognitive outcomes, we performed quantitative proteomics to determine the altered protein network during this early stage in tauopathy and compare this model with the human Alzheimer's disease (AD) proteome. We identified a cluster of preserved pathways shared with human tauopathy with striking potential for broad multi-target kinase intervention. We further report high confidence candidate proteins as novel therapeutically relevant targets for the treatment of tauopathy. Proteomics data are available via ProteomeXchange with identifier PXD023562.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据